PCOS Has Been Renamed PMOS: What This Means for You

This is not a minor administrative change. It is a significant moment in the recognition of a condition that has been misunderstood, misnamed and mismanaged for decades. Here is what you need to know.

Why Was the Name Changed?

The term Polycystic Ovary Syndrome has long been recognised by clinicians and patients as a misnomer. The name implies the presence of pathological ovarian cysts, but this is not what the condition involves. The structures seen on ultrasound in women with PCOS are not cysts at all. They are arrested follicles, small fluid-filled sacs containing immature eggs that have failed to develop and release normally.

This distinction matters enormously. Because the name pointed to the ovaries and to cysts, the broader hormonal and metabolic nature of the condition was consistently overlooked. Women were told they had a gynaecological problem when in fact they had a complex, multisystem endocrine disorder.

The consequences were severe. Research shows that up to 70% of women with the condition were never formally diagnosed. Fragmented care, stigma, confusion and delayed access to treatment became the norm rather than the exception.

What Does PMOS Stand For?

The new name, Polyendocrine Metabolic Ovarian Syndrome, was chosen for specific clinical reasons:

• Polyendocrine: Recognises that the condition involves multiple interacting hormonal disturbances, including insulin resistance, elevated androgens (such as testosterone), and neuroendocrine dysregulation. It is not an isolated ovarian disorder.
• Metabolic: Acknowledges the significant metabolic features of the condition, including insulin resistance, increased risk of type 2 diabetes, and cardiovascular disease. These have long been underemphasised under the old name.
• Ovarian: Retains the reference to the ovaries, which remain central to the condition without being overstated as the primary site of pathology.
• Syndrome: Retained from the original name to reflect that this is a cluster of features rather than a single pathological entity.

How Common Is PMOS?

PMOS affects approximately 1 in 8 women globally, equating to over 170 million people worldwide. It is one of the most common hormonal conditions in women of reproductive age, yet it remains significantly underdiagnosed.

Diagnosis is confirmed when at least two of three criteria are present: ovulatory dysfunction, hyperandrogenism, or polycystic ovarian morphology on ultrasound or elevated anti-Mullerian hormone levels.

What Are the Symptoms of PMOS?

• PMOS is a multisystem condition with a wide range of presentations. Symptoms can include:
• Irregular, infrequent or absent periods
• Difficulty conceiving due to irregular ovulation
• Excess androgen effects including acne, oily skin and hirsutism (excess facial or body hair)
• Thinning hair or hair loss on the scalp
• Weight gain, particularly around the abdomen, and difficulty losing weight
• Insulin resistance and increased risk of type 2 diabetes
• Fatigue and low energy
• Mood changes, anxiety and depression
• Sleep disturbance, including obstructive sleep apnoea
• Increased cardiovascular risk including elevated cholesterol and blood pressure

It is important to note that not every woman with PMOS will experience all of these symptoms. The condition presents differently in different women, which is one of the reasons it has historically been so difficult to diagnose.

PMOS and Hormonal Health Across the Lifespan

PMOS does not affect women only during their reproductive years. The hormonal and metabolic disruptions associated with the condition persist and evolve throughout a woman's life, including during perimenopause and menopause.

Women with PMOS approaching perimenopause may find that their symptoms shift. The androgen excess that was prominent in earlier years may diminish somewhat, while metabolic features such as insulin resistance and weight gain can become more pronounced as oestrogen levels begin to decline.

This is one of the reasons why specialist hormonal care throughout a woman's life is so important. PMOS does not resolve at menopause, and women who have lived with the condition deserve ongoing, joined-up support.

What Does This Name Change Mean in Practice?

The renaming of PCOS to PMOS will be accompanied by a three-year transition period, supported by an international education and awareness campaign. Clinical guidelines, medical education and international disease classification systems will all be updated to reflect the new terminology.

• In practical terms, this means:
• Clinicians will be encouraged to approach the condition as a hormonal and metabolic disorder rather than primarily a gynaecological one
• Diagnosis may improve as the focus broadens beyond ovarian morphology to include the full endocrine and metabolic picture
• Treatment approaches are likely to evolve, with greater emphasis on metabolic management, cardiovascular risk reduction and psychological support
• Women who have previously been told they have PCOS will not need to be rediagnosed - the condition is the same, the name has changed

How We Approach PMOS at The Women's Hormone Clinic

At The Women's Hormone Clinic, we have always taken a whole-person approach to hormonal health. We treat each woman as an individual, considering the full picture of her symptoms, history, metabolic health and goals rather than reducing care to a single label or a single organ.

For women with PMOS, this means a thorough assessment of hormonal and metabolic markers, personalised treatment planning, and ongoing support across the lifespan. We work with women from their teenage years through to post-menopause, recognising that PMOS does not define a single chapter of life.

If you have been diagnosed with PCOS and have questions about what the new name means for your care, or if you have been struggling with symptoms that you think may be related to PMOS and have never received a clear diagnosis, we would be glad to help.

A Step in the Right Direction

The renaming of PCOS to PMOS is more than a semantic change. It is a recognition that language shapes how conditions are understood, diagnosed and treated, and that women with this condition have long deserved better.

Over 170 million women worldwide live with this condition. For too long, a misleading name contributed to their symptoms being dismissed, their diagnoses delayed and their treatment fragmented. The global medical community has now listened. That matters.

Book a consultation at The Women's Hormone Clinic

References

Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published 12th May 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext

For informational purposes only. Always seek personalised advice from a qualified clinician. If something does not feel right, contact your prescriber.